Literature DB >> 15711205

Defence molecules in intestinal innate immunity against bacterial infections.

Lars Eckmann1.   

Abstract

PURPOSE OF REVIEW: Antimicrobial proteins are key effector molecules of innate immunity. The review discusses recent progress in understanding the function of these host defence molecules in intestinal physiology. RECENT
FINDINGS: All antimicrobial proteins can inhibit or kill bacteria in vitro, but differ markedly in their localization, regulation, and additional activities. alpha-Defensins are expressed constitutively in human neutrophils and small intestinal Paneth cells, where they require proteolytic processing and signal-induced release to be active in the intestinal lumen. Neutrophil-derived alpha-defensins can inhibit angiogenesis. Cryptdin-related sequence peptides form a subfamily of alpha-defensins in murine but not human Paneth cells that can form covalently linked heterodimers, leading to increased structural diversity and antimicrobial target range. Human beta-defensins (hBD) are expressed prominently in epithelial cells of the intestinal tract and other organs exposed to the environment. Their epithelial production is either constitutive, as exemplified by hBD-1, or strongly inducible, as shown for hBD-2,-3, and -4. Human cathelicidin, LL-37/hCAP18, is expressed constitutively by differentiated epithelial cells in the colon and stomach, but not the small intestine, as well as neutrophils and mast cells. It has multiple functions beyond its antimicrobial activity, including promotion of angiogenesis, attraction of leukocyte subsets, and activation of chemokine secretion. Angiogenins are a family of host defence-related ribonucleases, of which at least one is secreted by murine Paneth cells.
SUMMARY: The differential expression of diverse antimicrobial proteins in the gastrointestinal tract suggests that they occupy distinct functional niches in mucosal innate defence, which holds promise for pharmacological exploitation of their antimicrobial properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711205     DOI: 10.1097/01.mog.0000153311.97832.8c

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  24 in total

Review 1.  Innate immune response in the gut against Salmonella - review.

Authors:  I Trebichavský; I Splíchal; A Splíchalová
Journal:  Folia Microbiol (Praha)       Date:  2010-06-06       Impact factor: 2.099

2.  Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis.

Authors:  Satheesh K Sainathan; Kumar S Bishnupuri; Konrad Aden; Qizhi Luo; Courtney W Houchen; Shrikant Anant; Brian K Dieckgraefe
Journal:  Inflamm Bowel Dis       Date:  2011-09-26       Impact factor: 5.325

Review 3.  The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

4.  Innate barriers against infection and associated disorders.

Authors:  Richard L Gallo; Victor Nizet
Journal:  Drug Discov Today Dis Mech       Date:  2008-06-01

5.  New horizons for the infectious diseases specialist: how gut microflora promote health and disease.

Authors:  Shervin Rabizadeh; Cynthia Sears
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

6.  Cathelicidin signaling via the Toll-like receptor protects against colitis in mice.

Authors:  Hon Wai Koon; David Q Shih; Jeremy Chen; Kyriaki Bakirtzi; Tressia C Hing; Ivy Law; Samantha Ho; Ryan Ichikawa; Dezheng Zhao; Hua Xu; Richard Gallo; Paul Dempsey; Genhong Cheng; Stephan R Targan; Charalabos Pothoulakis
Journal:  Gastroenterology       Date:  2011-07-14       Impact factor: 22.682

7.  Expression of human beta-defensins in children with chronic inflammatory bowel disease.

Authors:  Matthias Zilbauer; Andreas Jenke; Gundula Wenzel; Jan Postberg; Andreas Heusch; Alan D Phillips; Gabriele Noble-Jamieson; Franco Torrente; Camilla Salvestrini; Robert Heuschkel; Stefan Wirth
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

8.  Reduced mucosal antimicrobial activity in Crohn's disease of the colon.

Authors:  Sabine Nuding; Klaus Fellermann; Jan Wehkamp; Eduard F Stange
Journal:  Gut       Date:  2007-04-24       Impact factor: 23.059

9.  The Clostridium difficile Dlt Pathway Is Controlled by the Extracytoplasmic Function Sigma Factor σV in Response to Lysozyme.

Authors:  Emily C Woods; Kathryn L Nawrocki; Jose M Suárez; Shonna M McBride
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

Review 10.  Necrotizing enterocolitis: a multifactorial disease with no cure.

Authors:  Kareena-L Schnabl; John-E Van Aerde; Alan-Br Thomson; Michael-T Clandinin
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.